A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-19. Anything still debated is marked as such rather than presented as settled.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Foods that contain nicotinamide include yeast, meat, milk, and green vegetables. Nicotinamide was discovered between 1935 and 1937. It is on the World Health Organization's List of Essential Medicines. Nicotinamide is available as a generic medication and over the counter. Commercially, nicotinamide is made from either nicotinic acid (niacin) or nicotinonitrile. In some countries, grains have nicotinamide added to them. Extraterrestrial nicotinamide has been found in carbonaceous chondrite meteorites.
CT is the total inorganic carbon [CO2*] is the sum of carbon dioxide and carbonic acid concentrations ([CO2*] = [CO2] + [H2CO3]) [HCO−3] is the bicarbonate concentration [CO2−3] is the carbonate concentration Each of these species are related by the following pH-driven chemical equilibria:
== Etymology == Naja christyi was first described by Belgian-British zoologist George Albert Boulenger in 1904. The generic name Naja is a Latinisation of the Sanskrit word nāgá (नाग) meaning "cobra". The specific epithet, christyi, is in honor of Dr. Cuthbert Christy, who led several biological expeditions to the Democratic Republic of the Congo.
Radiation protection areas are spatial areas in which either people can receive certain body doses during their stay or in which a certain local dose rate is exceeded. They are defined in § 36 of the Radiation Protection Ordinance and in §§ 19 and 20 of the X-Ray Ordinance. According to the Radiation Protection Ordinance, radiation protection areas are divided into restricted areas (local dose rate ≥ 3 mSv/hour), control areas (effective dose > 6 mSv/year) and monitoring areas (effective dose > 1 mSv/year), depending on the hazard.
==== Genomics ==== Genomics: Study of the genomes of organisms. Cognitive genomics: Study of the changes in cognitive processes associated with genetic profiles. Comparative genomics: Study of the relationship of genome structure and function across different biological species or strains. Functional genomics: Describes gene and protein functions and interactions (often uses transcriptomics). Metagenomics: Study of metagenomes, i.e., genetic material recovered directly from environmental samples. Neurogenomics: Study of genetic influences on the development and function of the nervous system. Pangenomics: Study of the entire collection of genes or genomes found within a given species. Personal genomics: Branch of genomics concerned with the sequencing and analysis of the genome of an individual. Once the genotypes are known, the individual's genotype can be compared with the published literature to determine likelihood of trait expression and disease risk. Helps in Personalized Medicine Electromics: Branch of genomics concerned with the role of exogenous electric fields in potentiating the gene expression profiles of cells, tissues, and organoids.
Sources: en.wikipedia.org
Flunarizine, sold under the brand name Sibelium among others, is a drug classified as a calcium antagonist which is used for various indications. It is not available by prescription in the United States or Japan. The drug was discovered at Janssen Pharmaceutica (R14950) in 1968.
An exhaustive review article published in March 2009 described the latest information on arteritic and non-arteritic ischemic optic neuropathy, both anterior (A-AION and NA-AION) and posterior (A-PION, NA-PION, and surgical).
The downy woodpecker and hairy woodpecker look almost the same, as do some 'Chrysocolaptes and Dinopium flamebacks, the smoky-brown woodpecker and some Veniliornis species, and other Veniliornis species and certain "Picoides" and Piculus. In neither case are the similar species particularly close relatives. Many birds of Australia, like wrens and robins, look like Northern Hemisphere birds but are not related. Oilbirds like microbats and toothed whales developed sonar-like echolocation systems used for locating prey. The brain structure, forebrain, of hummingbirds, songbirds, and parrots responsible for vocal learning (not by instinct) is very similar. These types of birds are not closely related. Seriemas and secretary birds very closely resemble the ancient dromaeosaurid and troodontid dinosaurs. Both have evolved a retractable sickle-shaped claw on the second toe of each foot, both have feathers, and both are very similar in their overall physical appearance and lifestyle. Migrating birds like, Swainson's thrushes can have half the brain sleep with the other half awake. Dolphins, whales, Amazonian manatee and pinnipeds can do the same. Called unihemispheric slow-wave sleep. Brood parasitism, laying eggs in the nests of birds of other species, happens in types of birds that are not closely related. The charadriiform buttonquails closely resemble the galliform quails. Gallopheasants and junglefowl have similar tail-feathers but evolved them independently. Toucans and hornbills are very similar and occupy the same ecological niche, but are not closely related.
=== EC 1.3.8 With a flavin as acceptor === EC 1.3.8.1: short-chain acyl-CoA dehydrogenase EC 1.3.8.2: 4,4′-diapophytoene desaturase (4,4′-diapolycopene-forming) EC 1.3.8.3: (R)-benzylsuccinyl-CoA dehydrogenase EC 1.3.8.4: isovaleryl-CoA dehydrogenase EC 1.3.8.5: 2-methyl-branched-chain-enoyl-CoA reductase EC 1.3.8.6: glutaryl-CoA dehydrogenase (ETF) EC 1.3.8.7: medium-chain acyl-CoA dehydrogenase EC 1.3.8.8: long-chain acyl-CoA dehydrogenase EC 1.3.8.9: very-long-chain acyl-CoA dehydrogenase EC 1.3.8.10: cyclohex-1-ene-1-carbonyl-CoA dehydrogenase EC 1.3.8.11: cyclohexane-1-carbonyl-CoA dehydrogenase (electron-transfer flavoprotein) EC 1.3.8.12: (2S)-methylsuccinyl-CoA dehydrogenase EC 1.3.8.13: crotonobetainyl-CoA reductase EC 1.3.8.14: L-prolyl-[peptidyl-carrier protein] dehydrogenase EC 1.3.8.15: 3-(aryl)acrylate reductase EC 1.3.8.16: 2-amino-4-deoxychorismate dehydrogenase EC 1.3.8.17: dehydro coenzyme F420 reductase
=== Reversible pulpitis === Reversible pulpitis is a mild to moderate inflammation caused by any momentary irritation or stimulant whereby no pain is felt upon the stimulants' removal. The pulp swells when the protective layers of enamel and dentine are compromised. Unlike irreversible pulpitis, the pulp gives a regular response to sensibility tests and inflammation resolves with management of the cause. No significant radiographic changes are present in the periapical region. Further examination is required to ensure that the dental pulp has returned to its normal state.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.